Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study

Helena Faust, Kristin Andersson, Tapio Luostarinen, Randi E. Gislefoss and Joakim Dillner
Helena Faust
1Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kristin Andersson
2Department of Occupational and Environmental Medicine, Lund University, Lund, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tapio Luostarinen
1Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
3Finnish Cancer Registry, Helsinki, Finland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randi E. Gislefoss
4Cancer Registry of Norway, Institute of Population-Based Cancer Research, Oslo, Norway.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joakim Dillner
1Department of Laboratory Medicine, Division of Pathology, Karolinska Institute, Stockholm, Sweden.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Joakim.Dillner@ki.se
DOI: 10.1158/1055-9965.EPI-15-1290 Published April 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Cutaneous human papillomavirus (HPV) types have been associated with non-melanoma skin cancer (NMSC), including a previous nested case–control study using HPV serology with bacterially derived fusion proteins with the major HPV capsid protein L1 (GST-L1). However, HPV serology using conformationally intact pseudovirions has been shown to correlate better with natural infection. Prospective studies using a more valid marker of infection are therefore warranted.

Methods: Cancer registry follow-up of large Nordic biobanks identified prediagnostic serum samples from 633 subjects who later developed SCC, 1,990 subjects who developed basal cell carcinoma (BCC). The samples from cases and matched controls were tested for IgG to pseudovirions to 16 different HPV types (3, 5, 6, 11, 15, 16, 18, 31, 32, 33, 38, 45, 52, 58, 68, and 76) and two polyomaviruses (MCPyV and JCPyV).

Results: Baseline seropositivity was not associated with SCC risk, and there were only weak associations with BCC risk [HPV-5 (OR, 1.1; 95% confidence interval [CI], 1.0–1.3), HPV-15 (OR, 1.2; 95% CI, 1.0–1.4), HPV-38 (OR, 1.2; 95% CI, 1.0–1.3), and MCPyV (OR, 1.1; 95% CI, 1.0–1.3)]. Acquisition of HPV-5 seropositivity during follow-up was associated with SCC risk (OR, 3.2; 95% CI, 1.3–7.6). Persistent seropositivity for HPV-15 was weakly associated with BCC (OR, 1.4; 95% CI, 1.0–1.9) and HPV-6 antibody persistence was weakly associated with SCC (OR, 2.2; 95% CI, 1.0–4.8).

Conclusion: Considering the large number of viruses tested, the weak associations found do not support any strong links between studied HPV and NMSC, with the possible exception of HPV-5 seroconversion and SCC.

Impact: Known alpha and beta papillomaviruses do not appear to be risk factors for NMSC. Cancer Epidemiol Biomarkers Prev; 25(4); 721–4. ©2016 AACR.

Introduction

Immunosuppression greatly raises the risk for nonmelanoma skin cancer (NMSC). Activation of oncogenic skin viruses has been proposed as a possible explanation. Cutaneous papillomaviruses infect healthy skin and are found in skin lesions such as actinic keratosis (AK) and squamous cell carcinoma (SCC) of the skin (1). Prospective human papillomavirus (HPV) seroepidemiology has been instrumental in providing prospective evidence supporting the causal association between HPV and cervical, anogenital, and oropharyngeal cancers (2).

Previously, we reported weak associations between HPV types 3, 15, 38, and 76 and future risk of SCC (3). The previous study was carried out using an HPV serologic method (GST-L1 fusion proteins) that has only weak association with HPV infection (4). Using a conformational HPV antigen (pseudovirions), HPV serology shows a better correlation to HPV infection (4). To use the improved HPV serology for a large prospective study is, therefore, likely to be more informative regarding any possible role of HPV in skin cancer.

Materials and Methods

Cohorts and study design

The cohorts and the study design are previously described (3). One matched control was selected for each case. We could include 633 SCC cases with 3,115 samples and 1,990 BCC cases with 6,145 samples and the same numbers of controls. In the serial-samples analysis, there were 531 BCC and 256 SCC cases (and the same numbers of controls) that had at least 2 prediagnostic samples.

HPV serology using pseudovirions

Serology was performed as described previously (5). Pseudovirions of HPV 3, 5, 6, 11, 15, 16, 18, 31, 32, 33, 38, 45, 52, 58, 68, 76 and Human polyomaviruses Merkel Cell polyomavirus (MCPyV) and JC polyomaviruses (JCPyV) were included (4). Cut-off values to define seropositivity were calculated independently for each HPV type by analyzing the mean fluorescence intensity unit (MFI) values obtained from 141 children's sera (average 4 year old). The cut-off algorithm recommended by the global HPV LabNet (mean MFI value of a negative control serum panel plus 3 SDs; ref. 6) was used, except that the cutoff value had to be at least 250 MFI.

Statistical analysis

Relative risks were estimated as odds ratios and 95% confidence intervals (CI) by means of conditional logistic regression with SAS 9.4 software (SAS Institute, Inc). If the asymptotic model did not converge, median unbiased estimates of ORs were estimated by exact conditional logistic regression. Heterogeneity in the OR estimates was assessed with a likelihood ratio test.

Results

Seropositivity at baseline showed no association to future risk for SCC for any of the tested viruses and only weak association to BCC for HPV-5 (OR, 1.1; 95% CI, 1.0–1.3), HPV-15 (OR, 1.2; 95% CI, 1.0–1.4), HPV-38 (OR, 1.1; 95% CI, 1.0–1.3), and MCPyV (OR, 1.1; 95% CI, 1.0–1.3; Table 1). All beta-2 HPV types together had a weak association with future BCC (OR, 1.2; 95% CI, 1.1–1.4; Table 1). In analyses restricted to multiple samples, HPV-3 and the alpha-7 HPV group had weak associations with SCC at baseline (OR, 1.8; 95 % CI, 1.0–3.1 and OR, 2.2; 95 % CI, 1.0–4.9, respectively; Table 2). HPV-5 associated with SCC, if seropositivity was acquired during follow-up (OR, 3.2; 95% CI, 1.3–7.6; Table 2). Persistent HPV-6 seropositivity was weakly associated with SCC (OR, 2.2; 95% CI, 1.0–4.8; Table 2) and persistent seropositivity to HPV-15 and the HPV beta-2 group was weakly associated with BCC risk [(OR, 1.4; 95% CI, 1.0–1.9) and (OR, 1.4; 95% CI, 1.1–2.0), respectively; Table 3].

View this table:
  • View inline
  • View popup
Table 1.

Seropositivity at baseline among cases and risk for NMSC

View this table:
  • View inline
  • View popup
Table 2.

Seropositivity among cases and risk for SCC for individuals with at least two samplesa

View this table:
  • View inline
  • View popup
Table 3.

Seropositivity among cases and risk for BCC for individuals with at least two samples

Discussion

We report a large, prospective HPV serologic study with improved methodology to assess possible associations between HPV infections and future NMSC, as has been reported previously (3). In the current study, we found exactly the same result for HPV-15 and the HPV beta-2 group as in the previous study regarding association with BCC development if seropositive at baseline and for HPV-15 if persistently seropositive. The previously reported associations between HPV-3, 38, 76 or the beta-2 group and SCC (3) were not found in the current study.

All statistically significant associations were very weak and, considering the large number of viruses analyzed, might thus be attributable to chance. The strongest association was seen for acquired HPV-5 seropositivity and future SCC risk. In 2012, IARC classified HPV-5 as having "limited evidence” for carcinogenicity, mostly based on data from the epidermodysplasia verruciformis disease (7). We found that HPV-5 may be involved in skin SCC, also in the general population.

A majority of studied HPV types were genital/mucosal and were included as negative controls. Persistent seropositivity for HPV-6 was weakly associated with future SCC, most likely attributed to chance. As we only studied four different HPV types in the beta group, we cannot conclude that all cutaneous HPV are harmless. For example, a recently discovered HPV type (HPV-197) has been reported in a rather large proportion of SCC (8). Continued analysis of possible association between cutaneous HPV and skin cancer, using extended panels with additional pseudovirions from new HPV types may be warranted.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: K. Andersson, J. Dillner

Development of methodology: H. Faust, J. Dillner

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): H. Faust, K. Andersson, R.E. Gislefoss

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): H. Faust, K. Andersson, T. Luostarinen

Writing, review, and/or revision of the manuscript: H. Faust, K. Andersson, T. Luostarinen, R.E. Gislefoss, J. Dillner

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): T. Luostarinen

Study supervision: J. Dillner

Grant Support

J. Dillner has received financial support from the Swedish Cancer Society for this study.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors acknowledge financial support from the Swedish Cancer Society. The authors thank Christina Cavala for excellent technical assistance.

  • Received January 7, 2016.
  • Accepted January 20, 2016.
  • ©2016 American Association for Cancer Research.

References

  1. 1.↵
    1. Feltkamp MC,
    2. de Koning MN,
    3. Bavinck JN,
    4. Ter Schegget J
    . Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 2008;43:353–60.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dillner J
    . The serological response to papillomaviruses. Semin Cancer Biol 1999;9:423–30.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Andersson K,
    2. Michael KM,
    3. Luostarinen T,
    4. Waterboer T,
    5. Gislefoss R,
    6. Hakulinen T,
    7. et al.
    Prospective study of human papillomavirus seropositivity and risk of nonmelanoma skin cancer. Am J Epidemiol 2011;175:685–95.
    OpenUrl
  4. 4.↵
    1. Faust H,
    2. Andersson K,
    3. Forslund O,
    4. Dillner J
    . Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses correlated to presence of HPV DNA in skin. J Gen Virol 2013;94:1096–103
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Faust H,
    2. Knekt P,
    3. Forslund O,
    4. Dillner J
    . Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin-coated beads. J Gen Virol 2010;91:1840–8.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Eklund C,
    2. Unger ER,
    3. Nardelli-Haefliger D,
    4. Zhou T,
    5. Dillner J
    . International collaborative proficiency study of human papillomavirus type 16 serology. Vaccine 2012;30:294–9.
    OpenUrlPubMed
  7. 7.↵
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, International Agency for Research on Cancer. A review of human carcinogens: part B: biological agents. Lyon, France: International Agency for Research on Cancer; 2012. p. 475.
  8. 8.↵
    1. Arroyo Muhr LS,
    2. Hultin E,
    3. Bzhalava D,
    4. Eklund C,
    5. Lagheden C,
    6. Ekstrom J,
    7. et al.
    Human papillomavirus type 197 is commonly present in skin tumors. Int J Cancer 2015;136:2546–55.
    OpenUrlPubMed
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 25 (4)
April 2016
Volume 25, Issue 4
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study
Helena Faust, Kristin Andersson, Tapio Luostarinen, Randi E. Gislefoss and Joakim Dillner
Cancer Epidemiol Biomarkers Prev April 1 2016 (25) (4) 721-724; DOI: 10.1158/1055-9965.EPI-15-1290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cutaneous Human Papillomaviruses and Squamous Cell Carcinoma of the Skin: Nested Case–Control Study
Helena Faust, Kristin Andersson, Tapio Luostarinen, Randi E. Gislefoss and Joakim Dillner
Cancer Epidemiol Biomarkers Prev April 1 2016 (25) (4) 721-724; DOI: 10.1158/1055-9965.EPI-15-1290
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Associations of ACEi and ARB with CRC risk
  • PDE5 Inhibitor Use and Precursors of Colorectal Cancer
  • Association Between Serum Iron Biomarkers and Breast Cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement